These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22596261)

  • 1. CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice.
    Zhang J; Barefoot BE; Mo W; Deoliveira D; Son J; Cui X; Ramsburg E; Chen BJ
    Blood; 2012 Jun; 119(26):6344-53. PubMed ID: 22596261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.
    Chen BJ; Cui X; Sempowski GD; Liu C; Chao NJ
    Blood; 2004 Feb; 103(4):1534-41. PubMed ID: 14551132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host-reactive CD8+ memory stem cells in graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    Nat Med; 2005 Dec; 11(12):1299-305. PubMed ID: 16288282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.
    Ophir E; Eidelstein Y; Afik R; Bachar-Lustig E; Reisner Y
    Blood; 2010 Mar; 115(10):2095-104. PubMed ID: 20042725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.
    Shindo T; Kim TK; Benjamin CL; Wieder ED; Levy RB; Komanduri KV
    Blood; 2013 Jun; 121(23):4617-26. PubMed ID: 23575444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells.
    Anderson BE; Taylor PA; McNiff JM; Jain D; Demetris AJ; Panoskaltsis-Mortari A; Ager A; Blazar BR; Shlomchik WD; Shlomchik MJ
    Blood; 2008 May; 111(10):5242-51. PubMed ID: 18285547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of lymph node fibroblastic reticular cells and high endothelial cells is associated with humoral immunodeficiency in mouse graft-versus-host disease.
    Suenaga F; Ueha S; Abe J; Kosugi-Kanaya M; Wang Y; Yokoyama A; Shono Y; Shand FH; Morishita Y; Kunisawa J; Sato S; Kiyono H; Matsushima K
    J Immunol; 2015 Jan; 194(1):398-406. PubMed ID: 25422510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory CD4+ T cells do not induce graft-versus-host disease.
    Anderson BE; McNiff J; Yan J; Doyle H; Mamula M; Shlomchik MJ; Shlomchik WD
    J Clin Invest; 2003 Jul; 112(1):101-8. PubMed ID: 12840064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human CD62L- memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion.
    Foster AE; Marangolo M; Sartor MM; Alexander SI; Hu M; Bradstock KF; Gottlieb DJ
    Blood; 2004 Oct; 104(8):2403-9. PubMed ID: 15231569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
    Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.
    Mochizuki K; Meng L; Mochizuki I; Tong Q; He S; Liu Y; Purushe J; Fung H; Zaidi MR; Zhang Y; Reshef R; Blazar BR; Yagita H; Mineishi S; Zhang Y
    Blood; 2016 Jun; 127(25):3270-80. PubMed ID: 27143255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired effector memory T-cell regulation facilitates graft versus host disease in CCR7-deficient bone marrow transplant chimeras.
    de Jager SC; Canté-Barrett K; Bot I; Husberg C; van Puijvelde GH; van Santbrink PJ; Yndestad A; van den Oever JM; Kuiper J; van Berkel TJ; Lipp M; Zwaginga JJ; Fibbe WE; Aukrust P; Biessen EA
    Transplantation; 2009 Sep; 88(5):631-9. PubMed ID: 19741459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic memory T cell response.
    Chen BJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):20-2. PubMed ID: 19418623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD.
    Ermann J; Hoffmann P; Edinger M; Dutt S; Blankenberg FG; Higgins JP; Negrin RS; Fathman CG; Strober S
    Blood; 2005 Mar; 105(5):2220-6. PubMed ID: 15546950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early effector cells survive the contraction phase in malaria infection and generate both central and effector memory T cells.
    Opata MM; Carpio VH; Ibitokou SA; Dillon BE; Obiero JM; Stephens R
    J Immunol; 2015 Jun; 194(11):5346-54. PubMed ID: 25911759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New developments in allotransplant immunology.
    Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
    Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.
    Hossain MS; Jaye DL; Pollack BP; Farris AB; Tselanyane ML; David E; Roback JD; Gewirtz AT; Waller EK
    J Immunol; 2011 Nov; 187(10):5130-40. PubMed ID: 22013117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.